Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Indtil det natten mellem tirsdag og onsdag stod klart, at Demokraatit blev Grønlands største parti, var partiformand ...
Zealand-aktien dykker kraftigt – Novo stigerOpdateret kl. 09.47. Københavns Fondsbørs har skudt gang i handlen torsdag, hvor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback